A prospective, randomized, double-blind, placebo-controlled, single bolus, multi-national, multi-center, parallel group, dose ranging study of desmoteplase (INN) in the indication of acute ischemic stroke.

This international trial involves the use of desmoteplase in the treatment of acute stroke in the range of 3-9 hours after stroke onset. Selected patients have a 2 out of 3 chance of receiving the study medication. Desmoteplase is a highly fibrin-selective plasminogen activator derived from vampire bat saliva.

The subject has been invited to participate in this study because he/she appears to have a type of stroke called acute intracerebral hemorrhage (ICH) that is likely to have resulted from a small blood vessel bursting deep in the brain. The amount of blood in the subject’s brain because of this burst in the blood vessel may increase in size and cause additional injury to the brain. The treatment options currently available for the condition are restricted to supportive care. No specific treatment for ICH exists today. Surgery may be applicable in certain cases, and the study doctor will discuss such surgical options with you, as appropriate.
The purpose of this study is to find out whether a study medication called NovoSeven? is effective and safe in the treatment of acute ICH. Approximately 475 patients with ICH will be enrolled in this research study worldwide.

The purpose of this study is to find out whether the study medication TS-011 is a safe and effective neuroprotectant. Animal studies have shown TS-011 to be a potent and selective inhibitor of the enzyme 20-HETE.

The primary objective is to evaluate the safety of TS-011 in acute ischemic stroke (AIS) patients. Secondary objectives of the study are to evaluate the pharmacokinetics (PK) of TS-011 and its metabolites, the pharmacodynamics (PD) of 20-hydroxyeicosatetraenoic acid (20-HETE) in response to escalation of TS-011 dose, and to obtain preliminary efficacy data in AIS patients using standard stroke scales [modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS) and Barthel Index (BI)] following TS-011 infusion.

The primary objective of this study is to determine whether patients who suffered acute ischemic stroke and received Ancrod (Virpinex) intravenously within 6 hours from the symptoms onset, experience improvement of their stroke symptoms, thus reducing disability within the next 90 days .

The purpose of this study is determine the effects of using of a combination of two drugs--integrilin (eptifibatide) and activase (recombinant tissue plasminogen activator, rt-PA, or recombinant t-PA)--to dissolve blood clots in patients who have a stroke.

MR AND RECANALIZATION OF STROKE CLOTS USING EMBOLECTOMY Patients under 85 who present within 7 hours with acute ischemic stroke occurring in the MCA territory are eligible for enrollment. They are randomized to either treatment with the Merci Retriever® or best medical management. They must be eligible for MRI in order to be enrolled. 120 patients will be enrolled nationwide at 20 centers.

The Field Administration of Stroke Therapy-Magnesium (FAST-MAG) trial will examine if magnesium sulfate can protect the threatened brain when administered to stroke victims by paramedics within the first two hours of stroke onset. Magnesium sulfate works by dilating brain blood vessels and by preventing buildup of damaging calcium in injured nerve cells.

The National Institutes of Health-funded FAST-MAG trial is the first large-scale trial of neuroprotective therapy delivery to stroke patients in ambulances.

The FAST-MAG trial will be performed in conjunction with paramedics from the Los Angeles Fire Department, as well as emergency physicians, neurologists and nurses throughout Los Angeles County.

The purpose of this study is to demonstrate the safety and efficacy of the NeuroFlo? treatment plus medical treatment relative to medical treatment alone in improving neurological outcome in the ischemic stroke patients

The NeuroFlo? is a dual balloon aortic catheter. The device is inserted through the femoral artery into the abdominal aorta and positioned so that the proximal and distal balloons are above and below the renal artery. The balloons are then inflated to reduce luminar area by 70% for 45 minutes. This reduces, but doesn’t occlude blood flow to the lower part of the body. Dual balloons and pressure measurements create a stable, controlled 70% occlusion. Cerebral perfusion increases average 30%+ and persist beyond balloon deflation.

ABCs of Stroke aims collect blood samples and clinical information that can be stored and later analyzed to discover information that might lead to new tests or treatments for acute stroke.